Item 1.01. Entry into a Material Definitive Agreement.
On January 4, 2021, Kura Oncology, Inc., (the "Company"), entered into a Master
Collaboration Agreement and a project schedule, collectively the Agreement, with
Illumina, Inc. ("Illumina"). Pursuant to the Agreement, Illumina has agreed to
develop and commercialize an assay as a companion diagnostic test to identify
head and neck squamous cell carcinoma patients with an HRAS mutation for use
with tipifarnib, one of the Company's lead drug candidates.
Under the Agreement, Illumina is responsible for developing, and obtaining and
maintaining regulatory approvals for, the companion diagnostic test in the
United States, the United Kingdom and major European markets and such other
countries as the parties may mutually agree. In addition, Illumina has agreed to
use commercially reasonable efforts to manufacture the companion diagnostic test
and to make the companion diagnostic test commercially available in the United
States, the United Kingdom and major European markets and such other countries
as the parties may mutually agree.
The foregoing description of the material terms of the Agreement is qualified
in its entirety by reference to the complete text of the Agreement, which the
Company intends to file, with confidential terms redacted, with the Securities
and Exchange Commission as an exhibit to the Company's Annual Report on Form
10-K for the year ended December 31, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
KURA ONCOLOGY, INC. 
